Moderna shares jumped nearly 7% ahead of its scheduled inclusion in the Nasdaq 100 before the market opens on Oct. 9, closing ...

US pharmaceutical companies Moderna and Merck announced on the 19th local time that their jointly developed, patient-personalized mRNA cancer vaccine has met its primary endpoint of suppressing cancer ...

The biotech could play a significant role in a national effort to combat cancer.

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Moderna-Aktie steigt über 12% nach Rückkehr in den Nasdaq-100. Anleger erwarten positive Krebsforschungsergebnisse. COO Juan ...

Moderna株が急伸した。Nasdaq 100への採用を控えた買いが入り、5日の終値は前営業日比6.95%高の203.21ドルとなった。一方で、株価の過熱を警戒する見方も出ており、Citiは投資判断を「売り」に引き下げている。

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, ...

While Moderna’s total revenue dropped 40% in 2025, missing the company’s expectations, CEO Stéphane Bancel’s pay was roughly flat, with a 0.2% increase year on year. (Photo by FABRICE COFFRINI/AFP via ...

Berenberg sube el precio objetivo de Moderna hasta los 100 dólares por acción desde los 45 dólares por título previos tras los resultados positivos de su vacuna con Merck contra el melanoma, aunque ...

Wall Street vicino ai record, ma quattro titoli ricevono giudizi negativi. Le valutazioni delle banche e i livelli grafici di Apple, Costco, Moderna e Netflix ...